Cell and Gene Therapy, Industrial Impact

Making the Promise of mRNA a Reality: OvercomingScale-Up Challenges

March 22, 2023

Making the Promise of mRNA
If scaling issues strike you as obvious or even boring, you should read “On Being the Right Size,” a 1926 essay by geneticist J.B.S. Haldane. It makes the case that a difference in scale—a seemingly simple matter—may demand subtle changes in form and function.

Spotlight

Transposagen Biopharmaceuticals

Transposagen, Inc. is a privately-held biotechnology company founded in 2005 to commercialize early gene editing technology for the construction of rodent models of disease. Since then, Transposagen has significantly increased its scientific offerings to include a suite of gene editing technologies and services that address the research needs of both academic and drug discovery investigators.

OTHER WHITEPAPERS
news image

Early engagement and regulatory considerations for biotech

whitePaper | March 24, 2023

Biotechnology companies are at the epicenter of innovative drug development, with discoveries spanning from small molecules, large molecules, and biologics to genomic medicines and first-inclass immunotherapies.

Read More
news image

How Can Biotechnology and Pharmaceutical Industries Better Weather This New Economy?

whitePaper | October 10, 2022

Biotechnology and pharmaceutical industries continue to experience increased pressure on financial performance due to several factors.

Read More
news image

IoT To The Rescue For Biotech & Pharma Manufacturing

whitePaper | April 7, 2020

The Internet of Things (IoT) could not be timelier for biotech/pharma. With fierce cost pressures, the push for value-based outcomes, and the need for flexible manufacturing solutions, the IoT is the much-needed shot in the arm to bring about transformational change. Sensors, actuators, and devices (“things”) embedded in production equipment and networked through computer systems can generate an enormous amount of data. The data can be mined for insights and opportunities to drive production efficiency, automate monitoring and controlling functions, and enable flexible manufacturing systems.

Read More
news image

The EU Clinical Trials Regulation − What You Need to Know

whitePaper | March 22, 2022

The Clinical Trials Regulation has retained some definitions and refined others. For example the definition of “clinical study”: “Any investigation in relation to humans intended: (a) to discover or verify the clinical, pharmacological or other pharmacodynamic.

Read More
news image

bFGF Supports Human ES Cell Self-Renewal

whitePaper | March 24, 2023

Basic fibroblast growth factor (bFGF) is an important cytokine used to support the growth and self renewal of human embryonic stem cells.

Read More
news image

The US Bioeconomy

whitePaper | April 14, 2022

In the nearly 50 years since the first genetic engineering experiments, the United States has become the world’s biotechnology powerhouse,

Read More

Spotlight

Transposagen Biopharmaceuticals

Transposagen, Inc. is a privately-held biotechnology company founded in 2005 to commercialize early gene editing technology for the construction of rodent models of disease. Since then, Transposagen has significantly increased its scientific offerings to include a suite of gene editing technologies and services that address the research needs of both academic and drug discovery investigators.

Events